Bader Y. Alhatlani^{1*}, Waleed A. Aljabr², Mohammed S. Almarzouqi¹, Sami M. Alhatlani³,

Seroprevalence of the hepatitis E virus among blood

2 donors in the Qassim Region, Saudi Arabia

4	Rayan N. Alzunaydi ³ , Abeer S. Alsaykhan ³ , Sulaiman H. Almaiman ³ , Ahmed A. Aleid ⁴ ,
5	Ammar H. Alsughayir ⁵ , Yara E. Bishawri ² , Abdulrahman A. Almusallam ¹
6	
7	¹ Department of Medical Applied Sciences, Unayzah Community College, Qassim University,
8	Unayzah, Saudi Arabia
9	² Research Centre, King Fahad Medical City, Riyadh, Saudi Arabia
10	³ Blood Donor Unit, Medical Laboratory Department, King Saud Hospital, Unayzah, Saudi
11	Arabia
12	⁴ Gastroenterology and Hepatology Department, King Fahad Medical City, Riyadh, Saudi
13	Arabia
14	⁵ Transfusion Medicine and Hematopathology Department, King Fahad Medical City, Riyadh,
15	Saudi Arabia
16	
17	*Corresponding author
18	E-mail: <u>balhatlani@qu.edu.sa</u> (BYA)
19	
20	Short title: Prevalence of hepatitis E in blood donors in the Qassim Region
21	
22	
23	

24 25

It is made available under a CC-BY 4.0 International license .

26 Abstract

27	The aim of this study was to evaluate the seroprevalence of hepatitis E virus (HEV), a major
28	public health issue worldwide with the potential for transmission via blood transfusion, in
29	blood donors in the Qassim Region, Saudi Arabia. Serum samples $(n = 1,078)$ were collected
30	from volunteer blood donors from January to April 2019 and tested for the presence of anti-
31	HEV IgG and IgM by indirect enzyme-linked immunosorbent assays. Overall, the
32	seroprevalence of anti-HEV IgG and IgM among blood donors was 5.7% and 1.3%,
33	respectively. Additionally, the seropositive rates of anti-HEV IgG and IgM were significantly
34	higher in non-Saudi donors (22.1% and 7.8%) than in Saudi donors (3% and 0.2%). The
35	seroprevalence of anti-HEV IgG increased with age; however, there was no correlation
36	between gender and anti-HEV IgG and/or IgM. The seroprevalence of HEV among blood
37	donors in the Qassim Region was lower than previous estimates for other regions of the
38	country. Further studies covering a wider geographical area are needed to validate and
39	expand the findings and to determine the importance of HEV screening in the region.
40	
41	
42	
43	

It is made available under a CC-BY 4.0 International license .

45 Introduction

46 Hepatitis E virus (HEV), belonging to the *Orthohepevirus* genus in the family 47 *Hepeviridae*, causes liver diseases in humans [1]. The virus was first described in the early 48 1980s as a non-A and non-B hepatitis virus and was subsequently cloned in 1991 [2,3]. HEV 49 contains a small nonenveloped, positive-sense single-stranded RNA genome approximately 50 7,200 nucleotides long [4]. HEV is an etiological agent of hepatitis E in humans. Similar to 51 hepatitis A, the vast majority of HEV infections are asymptomatic (especially in children) or 52 cause self-limiting acute liver inflammation, which can resolve within a few weeks without 53 the need for specific treatment [4]. However, immunosuppressed individuals, organ-54 transplant recipients, hemodialysis patients, and pregnant women are at a high risk of 55 developing life-threatening diseases, including chronic hepatitis and acute liver failure, after 56 infection with HEV [5,6]. It has been estimated that the mortality rates for HEV infections in 57 pregnant women and young people are about 20% and 3%, respectively [7]. The incubation 58 period, which occurs during the prodromal phase, can vary from 2 to 8 weeks, and common 59 symptoms of HEV infection during this period are usually nonspecific and include fever, 60 nausea, vomiting, and malaise [8]. HEV is now recognized as a major public health issue, 61 causing over 20 million infections every year worldwide and accounting for approximately 62 70,000 deaths [1]. Currently, there are eight known HEV genotypes from only one serotype 63 that can infect humans and other animal taxa (HEV-1 to HEV-8), of which HEV-1 and HEV-64 2 are restricted to humans and are associated with most outbreaks in developing countries in 65 parts of Asia, Central America, and Africa [9]. Genotypes 3 and 4 are typically identified in 66 developed countries, including the USA, New Zealand, Japan, and some countries in Europe, 67 and can be isolated from a broader range of taxa, including humans, pigs, deer, and rabbits. 68 Genotypes 5 and 6 are found in wild boars [8,10]. More recently, a new genotype of camelid

It is made available under a CC-BY 4.0 International license .

69 HEV (HEV-7) was isolated from dromedary camels in the UAE and some African countries,

70 including Sudan and Egypt [11,12].

71 Fecal-oral transmission is considered the main route of HEV transmission, but other 72 transmission routes have been suggested. This includes person-to-person transmission, such 73 as vertical transmission (mother-to-infant) during delivery. In particular, blood transfusion 74 transmission has become one of the main routes, especially in some low-income countries in 75 Asia [4]. Several studies have reported transfusion-transmitted HEV from blood components 76 in many industrialized countries, including European countries, Australia, and the United 77 States [13-18]. In the Gulf and other neighboring countries, few studies have evaluated the 78 HEV seroprevalence in healthy blood donors. A recent study has indicated that the HEV 79 seroprevalence in Qatar is high among blood donors, i.e., approximately 21% [19]. To the 80 best of our knowledge, the first study of HEV in Saudi Arabia was conducted in 1994 in 81 Riyadh and Gizan, with anti-HEV antibody detection frequencies of 8.4% and 14.9%, 82 respectively [20]. Two additional studies of HEV in Saudi Arabia reported seroprevalences in 83 blood donation samples of 18.7% and 16.9% in Makkah and Jeddah, respectively [21,22]. In 84 most countries, screening is not available for HEV in blood donors. However, in the 85 Netherlands, screening was introduced in 2017, and the United States is now considering 86 HEV screening for blood donors [4]. In this study, we estimated the HEV screenere 87 among blood donors in the Qassim Region, Saudi Arabia. These results provide a basis for 88 evaluating whether routine screening is necessary in Saudi Arabia. 89

90 Materials and methods

91 Ethics statement and sample collection

It is made available under a CC-BY 4.0 International license .

92	From January to April 2019, 1,078 whole blood samples were collected from
93	volunteer blood donors at the Blood Donor Unit at King Saud Hospital, Unayzah, Saudi
94	Arabia. All study participants provided written informed consent, and the study design was
95	approved by the local research Ethical Committee of the General Directorate of Health
96	Affairs at Qassim Province (approval number: 1441-225162).
97	
98	Serological testing
99	Serum samples were tested for the presence of anti-HEV IgG and IgM antibodies
100	using commercial HEV Enzyme-linked Immunosorbent Assay (ELISA) Kits (Fortress
101	Diagnostics, Antrim, UK) according to the manufacturer's instructions. The sensitivity and

specificity of the assays are 99.5% and 99.6%, respectively [23]. Samples were tested in

103 duplicate and samples yielding borderline results were retested in duplicate to confirm the

104 initial results. Only IgG-positive samples were tested for the presence of anti-HEV IgM.

105

106 Statistical analyses

107 The Chi-square test and Fisher's exact text with the Freeman-Halton extension were 108 used to evaluate the associations between the demographic characteristics of the participants 109 and HEV seroprevalence. All statistical analyses were performed using an online statistical 110 calculator at: (https://www.socscistatistics.com); a two-tailed *p*-value of 0.05 was considered 111 significant.

112

113 **Results**

Whole blood samples (n = 1,078) were collected from blood donors at King Saud
Hospital in the Qassim Region, Saudi Arabia. General characteristics of the blood donors are

It is made available under a CC-BY 4.0 International license .

- summarized in Table 1. The study population included 1,002 (93%) men and 76 (7%)
- 117 women, with 924 (85.7%) Saudis and 154 (14.3%) non-Saudis with different nationalities.
- 118 The age of participants ranged from 18 to 73 years (mean \pm SD, 34.5 \pm 10.3 years); 461
- donors (42.8%) were aged 25 to 34 years, 202 donors (18.7%) were younger than 25 years,
- 120 and 61 donors (5.7%) were older than 55 years (Table 1).
- 121

122 Table 1. Characteristics of the study population and anti-HEV IgG results.

Gender	<u>Total (n = 1,078)</u>	HEV IgG-positive	HEV IgG-negative (n	<i>p</i> -value
	76 (7%)	<u>(n = 61)</u>	<u>= 1,017)</u>	
Female	1,002 (93%)	2 (2.6%)	74 (97.4%)	0.24
Male		59 (5.9%)	943 (94.1%)	
Nationality				
Saudi	924 (85.7%)	27 (3%)	897 (97%)	< 0.001
Non-Saudi	154 (14.3%)	34 (22.1%)	120 (77.9%)	
Age group (years)				
<25	202 (18.7%)	2 (1%)	200 (99%)	
25-34	461 (42.8%)	28 (6%)	433(94%)	0.01
35–44	247 (22.9%)	16 (6.5%)	231 (93.5%)	
45–54	107 (9.9%)	11 (10.3%)	96 (89.7%)	
≥55	61 (5.7%)	4 (6.5%)	57 (93.5%)	

¹²⁴

125	In total, 61 of the 1,078 blood samples (5.7%) were positive for anti-HEV IgG,
126	including 2 samples from women (2.6%) and 59 from men (5.9%), with no significant
127	difference between males and females ($p = 0.24$). However, the anti-HEV IgG seroprevalence
128	was significantly higher in non-Saudis (22.1%) than in Saudis (3%) (Table 1, $p < 0.001$). We
129	also analyzed the same blood donor samples for the seroprevalence of anti-HEV IgM. Our
130	results indicated that 14 of the 1,078 serum samples (1.3%) were positive for anti-HEV IgM
131	(Table 2). Again, the seroprevalence of anti-HEV IgM was significantly higher in blood
132	samples from non-Saudis (7.8%) than in those from Saudi donors (0.2%) (Table 2, $p < 1$

It is made available under a CC-BY 4.0 International license .

- 133 0.001). No significant differences were found in the frequencies of anti-HEV IgM-positive
- 134 samples between women and men (p = 0.99).
- 135

136 **Table 2. Characteristics of the study population and anti-HEV IgM results.**

Total	HEV IgM-positive	HEV IgM-negative (n =	<u><i>p</i>-value</u>
<u>(n = 1,078)</u>	(n = 14)	<u>1,064)</u>	
76 (7%)	1 (1.3%)	75 (99%)	0.99
1,002 (93%)	13 (1.3%)	989 (99%)	
924 (85.7%)	2 (0.2%)	922 (99.8%)	< 0.001
154 (14.3%)	12 (7.8%)	142 (92.2%)	
202 (18.7%)	2 (1%)	200 (99%)	
461 (42.8%)	6 (1.3%)	455 (98.7%)	0.72
247 (22.9%)	5 (2%)	242 (98%)	
107 (9.9%)	1 (1%)	106 (99%)	
61 (5.7%)	0 (0%)	61 (0%)	
	$ \begin{array}{r} \underline{(n = 1,078)} \\ 76 (7\%) \\ 1,002 (93\%) \\ 924 (85.7\%) \\ 154 (14.3\%) \\ 202 (18.7\%) \\ 461 (42.8\%) \\ 247 (22.9\%) \\ 107 (9.9\%) \\ \end{array} $	$\begin{array}{c cccc} \underline{(n=1,078)} & \underline{(n=14)} \\ \hline 76 (7\%) & 1 (1.3\%) \\ 1,002 (93\%) & 13 (1.3\%) \\ \hline 924 (85.7\%) & 2 (0.2\%) \\ 154 (14.3\%) & 12 (7.8\%) \\ \hline 202 (18.7\%) & 2 (1\%) \\ 461 (42.8\%) & 6 (1.3\%) \\ 247 (22.9\%) & 5 (2\%) \\ 107 (9.9\%) & 1 (1\%) \\ \hline \end{array}$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

¹³⁷

138	Furthermore, we found a significantly higher rate of HEV IgG-positive samples for
139	donors between 45 to 54 years old (10.3%, $p = 0.01$) than for other age groups, while donors
140	younger than 25 years old had only an anti-HEV IgG seropositive rate of 1% (Fig 1). The
141	other age groups had similar anti-HEV IgG seropositive rates, and there was no significant
142	association between age groups and anti-HEV IgM seropositivity ($p = 0.72$).
143 144	Figure 1. Age distributions of 1,078 blood donors positive for anti-HEV IgG and/or
145 146	IgM.
	IgM. Of the 14 anti-HEV IgM-positive serum samples, only two samples tested positive for
146	
146 147	Of the 14 anti-HEV IgM-positive serum samples, only two samples tested positive for
146 147 148	Of the 14 anti-HEV IgM-positive serum samples, only two samples tested positive for anti-HCV antibodies, both of which were from male non-Saudi donors. There was no

152 **Discussion**

It is made available under a CC-BY 4.0 International license .

153	HEV is a transfusion-transmissible virus, as evidenced by its detection in blood
154	donors in both developed and developing countries [24,25]. In the current study, we screened
155	1,078 serum samples from blood donors in the Qassim Region, Saudi Arabia for anti-HEV
156	IgG and IgM antibodies. This is the largest study of the seroprevalence of HEV in Saudi
157	Arabia to date with respect to the number of samples obtained from blood donors. Our results
158	indicated that the seroprevalence of HEV in blood donors is 5.7% for IgG and 1.3% for IgM.
159	In addition, we detected a significant difference between Saudis (3%) and non-Saudis
160	(22.1%) in the seroprevalence of anti-HEV IgG. The seroprevalence of anti-HEV IgM was
161	also significantly higher among non-Saudi blood donors (7.8%) than in Saudi blood donors
162	(only 0.2%). Moreover, we found an increase in the rate of anti-HEV IgG with age. The
163	highest rate of positive anti-HEV IgG results was observed in the 45- to 54-year-old group
164	and the lowest rate was obtained for donors younger than 25 years (Fig 1). These results are
165	consistent with those of a previous study suggesting that age is a risk factor for HEV [26].
166	The anti-HEV IgM seroprevalence was comparable in all age groups other than donors aged
167	over 55 years who tested negative for IgM. Some studies have suggested that the HEV
168	seroprevalence rate increases with age, while other studies have reported that the correlation
169	between age groups and HEV seroprevalence varies [13, 22]. The anti-HEV IgG
170	seroprevalence among blood donors in the Qassim Region was comparable to that in Riyadh
171	(8.4%) but was much lower than estimates for other regions of Saudi Arabia, such as Gizan
172	(14.9%), Makkah (18.7%), and Jeddah (16.9%) [20-22]. Moreover, the seroprevalence of
173	anti-HEV IgG was also lower than that reported in neighboring countries, such as Qatar
174	(20.7%) [19]. This variation in the HEV seroprevalence among studies can be explained by
175	differences in the commercial enzyme immunoassays used to detect HEV antibodies in blood
176	donor samples. Commercial ELISA assays have different sensitivities and specificities,
177	which may lead to variation in estimates of the HEV seroprevalence [23]. For instance, the

It is made available under a CC-BY 4.0 International license .

178	HEV ELISA kit used in the present study (Fortress Diagnostics) has a sensitivity and
179	specificity of 99.5% and 99.6%, respectively, but the most common ELISA for HEV
180	detection (the Wantai assay) is known for its high antibody detection rates [24]. In addition,
181	these assays may not detect all HEV genotypes. The variation among studies may also be
182	explained by differences in demographic properties, which can vary among cities within the
183	same country. For example, the higher HEV seroprevalence in Makkah and Jeddah compared
184	to other cities in Saudi Arabia could be due to the high number of visitors of different
185	nationalities in these two cities every year for pilgrimages and other religious practices. A
186	potential limitation of the current study is that we could not confirm the presence of HEV
187	RNA in the seropositive donor samples.
188	In summary, we showed that the seroprevalence of HEV is relatively low (5.7% and
189	1.3% for anti-HEV IgG and IgM, respectively) among blood donors in the Qassim Region,
189 190	1.3% for anti-HEV IgG and IgM, respectively) among blood donors in the Qassim Region, Saudi Arabia when compared to those in other regions of the country. The anti-HEV IgG
190	Saudi Arabia when compared to those in other regions of the country. The anti-HEV IgG
190 191	Saudi Arabia when compared to those in other regions of the country. The anti-HEV IgG seropositivity was significantly higher in non-Saudi donors (22.1%) than in Saudi donors
190 191 192	Saudi Arabia when compared to those in other regions of the country. The anti-HEV IgG seropositivity was significantly higher in non-Saudi donors (22.1%) than in Saudi donors (3%). Further investigations of the seroprevalence of HEV in a larger sample of blood donors
190 191 192 193	Saudi Arabia when compared to those in other regions of the country. The anti-HEV IgG seropositivity was significantly higher in non-Saudi donors (22.1%) than in Saudi donors (3%). Further investigations of the seroprevalence of HEV in a larger sample of blood donors from an expanded geographical distribution are needed to determine the need for HEV

196 Acknowledgments

The authors gratefully thank all the staff in the Medical Laboratory Department at
King Saud Hospital for their contribution to this study. We also would like to thank Editage
(www.editage.com) for English language editing.

200

201 **References**

It is made available under a CC-BY 4.0 International license .

202	1.	Debing Y.	Moradpour D. Nevts J.	Gouttenoire J. U	pdate on hepatitis e virology:
-----	----	-----------	-----------------------	------------------	--------------------------------

- 203 Implications for clinical practice. J Hepatol. 2016;65(1): 200–212. doi:
- 204 10.1016/j.jhep.2016.02.045.
- 205 2. Balayan MS, Andjaparidze AG, Savin Skaya SS, Ketiladze ES, Braginsky DM,
- 206 Suvinov AP, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the 207 fecal-oral route. Intervirology. 1983;20: 23–31. doi: 10.1159/000149370
- 208 3. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, et al. Isolation of a
- 209 cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis.
- 210 Science 1990;247: 1335–1339. doi: 10.1126/science.2107574.
- Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis
 E virus infection. Nat Rev Dis Primers. 2017;3:17086. doi: 10.1038/nrdp.2017.86.
- 5. Kamar N, Selves J, Mansuy J-M, Ouezzani L, Péron J-M, Guitard J, et al. Hepatitis E
- virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:
- 215 811–817. doi: 10.1056/NEJMoa0706992.
- 2166. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin
- 217 Microbiol Rev. 2014;27: 116–138. doi: 10.1128/CMR.00057-13.
- 218 7. Mushahwar IK. Hepatitis E virus: Molecular virology, clinical features, diagnosis,
- transmission, epidemiology, and prevention. J Med Virol. 2008;80: 646–658. doi:
- 220 10.1002/jmv.21116.
- Pérez-Gracia MT, García M, Suay B, Mateos-Lindemann ML. Current knowledge on
 hepatitis E. J Clin Transl Hepatol. 2015;3: 117–126.
- 9. Sooryanarain H, Meng XJ. Hepatitis E virus: reasons for emergence in humans. Curr
 Opin Virol. 2019;34: 10–17. doi: 10.1016/j.coviro.2018.11.006.
- 225 10. Forni D, Cagliani R, Clerici M, Sironi M. Origin and dispersal of Hepatitis E virus.
- 226 Emerg Microbes Infect. 2018;7(1): 11. doi: 10.1038/s41426-017-0009-6.

It is made available under a CC-BY 4.0 International license .

- 11. Woo PCY, Lau SKP, Teng JLL, Tsang AKL, Joseph M, Wong EYM, et al. New
- hepatitis E virus genotype in camels, the Middle East. Emerg Infect Dis. 2014;20:
- 229 1044–1048. doi: 10.3201/eid2006.140140.
- 230 12. Sridhar S, Teng JLL, Chiu TH, Lau SKP, Woo PCY. Hepatitis E virus genotypes and
- evolution: Emergence of camel hepatitis E variants. Int J Mol Sci. 2017;18: E869.
- doi: 10.3390/ijms18040869.
- 13. Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D,
- et al. Hepatitis E virus seroprevalence among blood donors in Southwest Switzerland.
- 235 PLoS One. 2011;6: e21150. doi: 10.1371/journal.pone.0021150
- 14. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach
 for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol.
- 238 2012;50: 2708–2713. doi: 10.1128/JCM.01119-12.
- 239 15. Gallian P, Lhomme S, Piquet Y, Sauné K, Abravanel F, Assal A, et al. Hepatitis E
- virus infections in blood donors, France. Emerg Infect Dis. 2014;20: 1914–1917.
- 241 https://doi.org/10.3201/eid2011.140516.
- 242 16. Pawlotsky JM. Hepatitis E screening for blood donations: an urgent need? Lancet.
 243 2014;384: 1729–1730. doi: 10.1016/S0140-6736(14)61187-9.
- 17. Shrestha AC, Shrestha AC, Seed CR, Flower RLP, Rooks KM, Keller AJ, et al.
- Hepatitis E virus and implications for blood supply safety, Australia. Emerg Infect
 Dis. 2014:20: 1940–1942. doi: 10.3201/eid2011.140412.
- 247 18. Ticehurst JR, Pisanic N, Forman MS, Ordak C, Heaney CD, Ong E, et al. Probable
- transmission of hepatitis E virus (HEV) via transfusion in the United States.
- 249 Transfusion. 2019;59: 1024–1034. doi: 10.1111/trf.15140.
- 250 19. Nasrallah GK, Al Absi ES, Ghandour R, Ali NH, Taleb S, Hedaya L, et al.
- 251 Seroprevalence of hepatitis E virus among blood donors in Qatar (2013-2016).

It is made available under a CC-BY 4.0 International license .

- 253 20. Arif M, Qattan I, al-Faleh F, Ramia S. Epidemiology of hepatitis E virus (HEV)
- 254 infection in Saudi Arabia. Ann Trop Med Parasitol. 1994;88: 163–168. doi:
- 255 10.1080/00034983.1994.11812854.
- 256 21. Abdelaal M, Zawawi TH, al Sobhi E, Jeje O, Gilpin C, Kinsara A, et al.
- 257 Epidemiology of hepatitis E virus in male blood donors in Jeddah, Saudi Arabia. Ir J
- 258 Med Sci. 1998;167: 94–96. doi: 10.1007/bf02937946.
- 259 22. Johargy AK, Mahomed MF, Khan MM, Kabrah S. Anti-hepatitis E virus
- seropositivity in a group of male blood donors in Makkah, Saudi Arabia. J Pak Med
 Assoc. 2013;63: 185–189.
- 262 23. Al-Sadeq DW, Majdalawieh AF, Mesleh AG, Abdalla OM, Nasrallah GK. Laboratory
- 263 challenges in the diagnosis of hepatitis E virus. J Med Microbiol. 2018;67: 466–480.
- doi: 10.1099/jmm.0.000706.
- 265 24. Nelson KE. Transfusion transmission of hepatitis E virus: an emerging issue. Ann
 266 Blood. 2017;2: 1-7. doi: 10.21037/aob.2017.09.02.
- 267 25. Capai L, Charrel R, Falchi A. Hepatitis E in high-income countries: What do we
- 268 know? And what are the knowledge gaps? Viruses. 2018;10: 1–23. doi:
- 269 10.3390/v10060285.
- 270 26. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in
- 271 developed countries. Lancet Infect Dis. 2008;8: 698–709. doi: 10.1016/S1473-
- 272 3099(08)70255-X.

